IP Library Granted Patent US 7,718,781
Granted Patent B2
US 7,718,781 · App. 10/902,772 · Granted May 18, 2010

Hydroxypyridonate and hydroxypyrimidinone chelating agents

Assignee: The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,718,781
App. No.
10/902,772
Granted
May 18, 2010
Kind
B2
Abstract

The present invention provides hydroxypyridinone and hydroxypyrimidone chelating agents. Also provides are Gd(III) complexes of these agents, which are useful as contrast enhancing agents for magnetic resonance imaging. The invention also provides methods of preparing the compounds of the invention, as well as methods of using the compounds in magnetic resonance imaging applications.

Claims (19)

1. A composition comprising a targeting group attached to a complex between a gadolinium (III) ion and an organic ligand, said complex comprising a structure according to Formula I:

wherein R 1 , R 2 , and R 3 are members independently selected from a linking member, H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, hydroxy, carboxy, amide, ester, and amino groups, with the proviso that when A is nitrogen, R 1 is other than amino, and with the further proviso that when E is nitrogen, R 3 is not present;

R 4 is a member selected from a linking member, H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, hydroxy, carboxy, amide, and ester groups; and

A, E and Z are members independently selected from carbon and nitrogen, said complex having a solubility in water of at least about 15 mM.

2. The composition according to claim 1 , wherein at least one of R 1 , R 2 , R 3 and R 4 comprises a linker attaching said complex to said targeting group.

3. The composition according to claim 2 wherein said linker has the structure

wherein Z 1 is a member selected from H, CH 2 , OR 10 , SR 10 , NHR 10 , OCOR 11 , OC(O)NHR 11 , NHC(O)OR 10 , OS(O) 2 OR 10 , and C(O)R 11 ;

R 10 represents H, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl;

R 11 is a member selected from H, OR 12 , NR 12 NH 2 , SH, C(O)R 12 , NR 12 H, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl;

R 12 is a member selected from H, and substituted or unsubstituted alkyl;

X is a member selected from CH 2 , O, S and NR 13 ;

R 13 is a member selected from H, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl; and

j and k are each independently selected from the integers 1 to 20.

4. The composition according to claim 1 , wherein said targeting group is a small molecule or a macromolecule selected from saccharides, lectins, receptors, receptor ligands, proteins, antibodies, poly(ethers), dendrimers and poly(amino acids).

5. The composition according to claim 1 wherein said complex is targeted to the blood pool.

6. The composition according to claim 5 wherein said complex binds to human serum albumin (HSA).

7. The composition according to claim 1 wherein said complex is targeted to a liver or a component of the reticuloendothelial system.

8. The composition according to claim 1 wherein said complex is selective for tumors.

9. The composition according to claim 8 wherein said targeting group is a sapphyrin.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jun 9, 2009
From: UNIVERSITY OF CALIFORNIA BERKELEY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 022797/0436 →
Continuity (4)
Continuation 1019450200 · Jul 12, 2002
Continuation PCTUS022602600 · Aug 13, 2002
Provisional Application 6031213200 · Aug 13, 2001
Related Publication 20050008570A1 · Jan 13, 2005